Format

Send to

Choose Destination
Diabetologia. 2016 Sep;59(9):2036-9. doi: 10.1007/s00125-016-4017-1. Epub 2016 Jun 15.

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.

Author information

1
Clinica Medica 3, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padova, Italy. paola.fioretto@unipd.it.
2
AstraZeneca, Gothenburg, Mölndal, Sweden.
3
AstraZeneca, Wilmington, Delaware, USA.

KEYWORDS:

Albuminuria; Dapagliflozin; Renal impairment; SGLT2 inhibition; Type 2 diabetes

PMID:
27306615
PMCID:
PMC4969341
DOI:
10.1007/s00125-016-4017-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center